Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain. Its development pipeline also includes other treatments, such as AVERSA buprenorphine and AVERSA methylphenidate. Additionally, Nutriband is working on exenatide for individuals with type 2 diabetes and follicle stimulating hormone as a treatment for infertility. The company also holds a licensing agreement with Rambam Med-Tech Ltd. to further the development of RAMBAM Closed System Transfer Devices. Nutriband Inc. was founded in 2016 and its main offices are located in Orlando, Florida.
Sector: Orthopedic, Prosthetic & Surgical Appliances & Supplies
Industry: Biotechnology
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 12.16M shares outstanding
USNutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches.
The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain.
Its development pipeline also includes other treatments, such as AVERSA buprenorphine and AVERSA methylphenidate.
Additionally, Nutriband is working on exenatide for individuals with type 2 diabetes and follicle stimulating hormone as a treatment for infertility.
The company also holds a licensing agreement with Rambam Med-Tech Ltd. to further the development of RAMBAM Closed System Transfer Devices. Nutriband Inc. was founded in 2016 and its main offices are located in Orlando, Florida.
Alan Smith, Ph.D.
Chief Operating Officer and President of 4P Therapeutics
Gareth Sheridan
Founder, Chief Executive Officer & Director
Gerald Goodman
Chief Financial Officer & Chief Accounting Officer
Irina Gram
Director
Employees
13
Country
US
Sector
Healthcare
Website
nutriband.com
Loading congressional disclosures…
based on 12.16M shares outstanding
US30d Avg
132.72K
60d Avg
93.77K
90d Avg
64.27K
